A5036552357- Lung Cancer Research Studies
- CNS Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cardiac tumors and thrombi
- Palliative Care and End-of-Life Issues
- Vitamin D Research Studies
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Neurology and Historical Studies
- Interprofessional Education and Collaboration
- Nanoparticles: synthesis and applications
- Acute Lymphoblastic Leukemia research
- Neuroendocrine Tumor Research Advances
- Vitamin C and Antioxidants Research
University of Iowa
2017-2024
University of Iowa Hospitals and Clinics
2020-2024
University of Georgia
1975-1976
City College of New York
1976
Science Center of Iowa
1976
John Wiley & Sons (United States)
1976
Drake University
1976
Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab ( DA ‐ ‐R) has become the standard of care for primary mediastinal B‐cell lymphoma PMBCL ) at many institutions despite limited data in multi‐centre setting. We report a large, retrospective analysis children adults treated ‐R to characterize outcomes evaluate prognostic factors. assessed 156 patients across 24 academic centres, including 38 118 adults....
Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration. Pre-clinical studies have reported that pharmacological ascorbate (P-AscH-) enhances NSCLC response to platinum-based therapy. We conducted phase II clinical trial combining P-AscH- carboplatin-paclitaxel chemotherapy.Chemotherapy naïve patients received 75 g twice per week intravenously carboplatin and paclitaxel...
Background Patients with small cell lung cancer (SCLC) often respond to first-line chemoimmunotherapy. However, relapse is inevitable and associated a poor prognosis. Treatments for relapsed SCLC, such as lurbinectedin topotecan, are limited by modest efficacy significant hematologic adverse events, leaving need newer therapeutic agents or regimens. The combination of gemcitabine nab-paclitaxel active safe in other types malignancies, pancreatic cancer. methods We conducted phase II trial...
e24065 Background: While hospice care offers many patients services promoting comfort and quality of life, the traditional model described in Medicare policy presents numerous barriers to utilization. Notably, since pays for all therapies related a terminal illness, are often forced make difficult choice stop disease-directed order enroll hospice. Poor provider understanding also contributes common scenario which is offered too late meaningful impact their families. These issues were...
Introduction: Treatment with dose-adjusted EPOCH chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institutions despite limited data in multi-center setting. We report a large, retrospective analysis children adults PMBCL treated DA-EPOCH-R to characterize outcomes, specifically assess both pediatric adult patients, evaluate potential prognostic factors. Methods: 156 patients across 24 academic medical centers were...